טוען...
A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer
Background: Cabozantinib targets tyrosine kinases including MET, vascular endothelial growth factor (VEGF) receptor 2, and rearranged during transfection (RET). Differentiated thyroid cancer (DTC) is a tumor type that may be sensitive to cabozantinib. Therefore, we evaluated cabozantinib in a cohort...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Mary Ann Liebert, Inc.
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4195402/ https://ncbi.nlm.nih.gov/pubmed/25102375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2014.0125 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|